Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …

Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …

New immuno-oncology therapies are improving cancer treatments beyond the former
standard of care, as evidenced by the recent and continuing clinical approvals for …

Cancer immunotherapy has emerged as a promising approach for the treatment of various
cancers. However, the immunosuppressive tumor microenvironment (TME) limits the efficacy …

The treatment of cancer, especially of various types of solid tumors, has been revolutionized
by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success …

Simple Summary Within this review article the authors provide an unbiased review of the
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …

Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well
as activate the innate and adaptive immune systems in patients. Thus, they have been …

After regular chemotherapy, the expression of programmed cell death ligand 1 (PD-L1) in
almost all kinds of cancers is significantly increased, leading to reduced efficacy of T cell …

PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor
immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD …

Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-
defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host …